VIEKIRA XR Drug Patent Profile

When do Viekira Xr patents expire, and what generic alternatives are available?

Viekira Xr is a drug marketed by Abbvie and is included in one NDA. There are eighteen patents protecting this drug.

This drug has five hundred and fifty-two patent family members in fifty-two countries.

The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Viekira Xr

Viekira Xr was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 2, 2035. This may change due to patent challenges or generic licensing.

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VIEKIRA XR

International Patents:	552
US Patents:	18
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	84
Drug Prices:	Drug price information for VIEKIRA XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIEKIRA XR
DailyMed Link:	VIEKIRA XR at DailyMed

See drug prices for VIEKIRA XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIEKIRA XR

Constraining patent/regulatory exclusivity:

9,333,204

NDA:

208624

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIEKIRA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 4
University of Florida	Phase 4
Patient-Centered Outcomes Research Institute	Phase 4

See all VIEKIRA XR clinical trials

US Patents and Regulatory Information for VIEKIRA XR

VIEKIRA XR is protected by eighteen US patents.

This potential generic entry date is based on patent 9,333,204.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,139,536
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,420,596		Y	Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,642,538		Y	Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,006,387
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,744,170		Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,685,984

Expired US Patents for VIEKIRA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	7,148,359
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	7,364,752
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	8,399,015
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	8,268,349

International Patents for VIEKIRA XR

When does loss-of-exclusivity occur for VIEKIRA XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIEKIRA XR around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	112012003510
Croatia	P20180999
Argentina	088463
Uruguay	33981
Canada	2736895
European Patent Office	3438106

Supplementary Protection Certificates for VIEKIRA XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	SPC/GB15/008	United Kingdom		PRODUCT NAME: DASABUVIR, OR A SALT THEREOF; REGISTERED: UK EU/1/14/983 20150119
2368890	C02368890/01	Switzerland		FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
2692346	712	Finland
2692346	PA2017033,C2692346	Lithuania		PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2692346	132017000122534	Italy		PRODUCT NAME: PIBRENTASVIR, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(MAVIRET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1213, 20170728
2340029	15C0021	France		PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119

VIEKIRA XR: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is VIEKIRA XR?

VIEKIRA XR is an orally administered, pan-genotypic interferon-free regimen for the treatment of chronic hepatitis C virus (HCV) infection. It is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir, with dasabuvir co-administered as a separate tablet. The drug was developed by AbbVie Inc.

What was VIEKIRA XR's Initial Market Positioning and Approval Timeline?

VIEKIRA XR received U.S. Food and Drug Administration (FDA) approval on December 19, 2014. It was approved for the treatment of genotype 1 chronic HCV infection in adult patients, with specific recommendations for treatment-naive and treatment-experienced individuals, including those with cirrhosis [1].

In Europe, the European Medicines Agency (EMA) granted marketing authorization in January 2015 for VIEKIRA Pak, a similar regimen that uses the same active ingredients but is packaged differently [2]. The U.S. indication was later expanded to include certain patients with genotype 4 HCV.

The drug was positioned as a direct-acting antiviral (DAA) therapy, offering a cure rate exceeding 90% in clinical trials for specific patient populations. Its key differentiator was its interferon-free nature, addressing a significant unmet need for patients who could not tolerate interferon-based therapies due to side effects or contraindications.

What are the Key Efficacy and Safety Data for VIEKIRA XR?

Clinical trials demonstrated high sustained virologic response (SVR12) rates, a key indicator of cure, for VIEKIRA XR.

• Treatment-Naive Patients (Genotype 1): Studies showed SVR12 rates above 95% in treatment-naive patients without cirrhosis when treated for 12 weeks [3].
• Treatment-Experienced Patients (Genotype 1): For patients who had previously received treatment but not a sustained response, SVR12 rates were also in the high 90s for certain regimens, often requiring 12 or 24 weeks of treatment depending on prior therapy and cirrhosis status [3, 4].
• Genotype 4: Approval for genotype 4 was supported by studies demonstrating comparable efficacy to genotype 1, with SVR12 rates generally above 90% [5].

Safety profiles were generally favorable, with the most common adverse events reported in clinical trials including fatigue, nausea, pruritus, and insomnia. Serious adverse events were rare. A significant safety consideration was the drug interaction profile, particularly with ethinyl estradiol-containing contraceptives, which required dose adjustments or avoidance of concomitant use due to ritonavir's potent CYP3A4 inhibition [6].

What was VIEKIRA XR's Competitive Landscape at Launch?

Upon its launch, VIEKIRA XR entered a rapidly evolving market for HCV treatment. The landscape was characterized by the emergence of highly effective DAA regimens that promised significantly improved cure rates and shorter treatment durations compared to older interferon-based therapies.

Key competitors at the time of VIEKIRA XR's launch included:

• Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) by Gilead Sciences: These drugs, approved in late 2013 and early 2014, respectively, were early market leaders. Harvoni, in particular, offered a pan-genotypic, interferon-free, ribavirin-free option for genotype 1, becoming a dominant force.
• Viekira Pak/Viekira XR by AbbVie: This regimen offered an alternative interferon-free option.
• Olysio (simeprevir) by Janssen Therapeutics: Initially approved in combination with pegylated interferon and ribavirin, its utility as a DAA alone or in combination with other DAAs evolved.

The competitive dynamic was intense, with rapid innovation and significant pricing strategies employed by manufacturers. The primary battlegrounds were cure rates, treatment duration, pan-genotypic coverage, and the elimination of interferon and ribavirin.

What were the Financial Performance and Sales Trajectory of VIEKIRA XR?

AbbVie reported significant initial sales for VIEKIRA XR, reflecting pent-up demand for highly effective HCV treatments. However, its trajectory was impacted by intense competition and evolving market dynamics.

• 2015: VIEKIRA XR, under the brand name VIEKIRA Pak in many markets, achieved substantial sales in its first full year of availability. AbbVie reported approximately $1.5 billion in sales for the regimen in 2015 [7].
• 2016: Sales continued to be strong, reaching approximately $1.7 billion for the year. This period represented the peak of its commercial performance [8].
• 2017-2019: Sales began to decline as newer, more convenient, and potentially more pan-genotypic regimens from competitors entered the market, particularly those offering ribavirin-free treatment for a broader range of genotypes. By 2019, VIEKIRA XR sales had decreased significantly. AbbVie reported approximately $770 million in sales for hepatitis C products in 2019, a decline from previous years, with VIEKIRA XR and its predecessors contributing to this trend [9].
• Post-2019: The market for HCV treatments continued to consolidate around a few dominant players offering highly effective pan-genotypic cures. VIEKIRA XR's market share diminished due to these competitive pressures and the introduction of next-generation therapies by AbbVie itself and other companies.

The initial high sales were driven by its status as one of the first interferon-free DAA options. However, the rapid pace of innovation in HCV treatment meant that VIEKIRA XR, while effective, was quickly followed by competitors offering simpler, broader-coverage regimens.

What are the Key Patent Expirations and Regulatory Exclusivities Affecting VIEKIRA XR?

The patent landscape for VIEKIRA XR is complex, involving multiple patents covering the active pharmaceutical ingredients (APIs), formulations, and methods of treatment.

• U.S. Patents: AbbVie holds several U.S. patents related to the components of VIEKIRA XR, including patents for ombitasvir, paritaprevir, ritonavir, and dasabuvir. Key patents for the individual compounds and their use in treating HCV were generally filed in the early to mid-2000s, leading to potential expiration dates in the mid-2020s or later, depending on patent term extensions and any additional patent filings. For example, patents covering the core molecules have expiration dates that can extend into the late 2020s or early 2030s [10].
• European Patents: Similar patent protection exists in Europe, with patent families covering the APIs and their therapeutic applications.
• Regulatory Exclusivity: In addition to patent protection, VIEKIRA XR benefited from regulatory exclusivities granted by regulatory agencies:
  • New Chemical Entity (NCE) Exclusivity: In the U.S., approval as a new drug typically grants 5 years of NCE exclusivity, preventing generic approval of the same NCE for other indications.
  • Data Exclusivity: This provides a period during which generic manufacturers cannot rely on the innovator's clinical trial data for their own applications. In the U.S., this is typically 5 years for NCEs, and can be extended.
  • Orphan Drug Exclusivity: Not applicable to VIEKIRA XR.
  • Patent Term Extension (PTE): In the U.S., patent holders can apply for an extension of patent terms to compensate for regulatory review delays. This can extend patent life by up to five years.

The interplay of these patents and exclusivities determines the period of market protection. Generic entry for VIEKIRA XR is contingent on the expiration of relevant patents and any granted exclusivities, as well as the successful challenge or circumvention of these protections by generic manufacturers. As of 2023, VIEKIRA XR remains under patent and exclusivity protection in major markets, but specific patent expiration dates for key patents are approaching, which will facilitate generic competition in the future [11].

What is the Outlook for VIEKIRA XR in the Evolving Hepatitis C Market?

The market for VIEKIRA XR is characterized by a declining trajectory due to several factors.

• Competition: The HCV market is dominated by highly effective, pan-genotypic regimens that offer simpler treatment protocols and broader coverage than VIEKIRA XR. These include AbbVie's own newer therapies like Mavyret (glecaprevir/pibrentasvir), which has a shorter treatment duration (8 weeks) and treats all six major HCV genotypes [12]. Competitors like Gilead's Epclusa (sofosbuvir/velpatasvir) also offer pan-genotypic coverage.
• Market Saturation: The significant success of early DAA therapies has led to a substantial portion of the prevalent HCV population in developed countries being treated and cured. This reduces the ongoing demand for new treatments.
• Shifting Treatment Paradigms: The focus is increasingly on reaching underserved populations and managing reinfection, rather than on the initial treatment of large, newly diagnosed cohorts.
• Pricing Pressures: While DAAs represent a significant investment, competition has led to price negotiations and formulary restrictions, impacting the profitability of older regimens.

AbbVie's strategic focus has shifted towards its newer, more advanced HCV therapies and other therapeutic areas. VIEKIRA XR is now considered a legacy product within its portfolio. Its sales are expected to continue to decline as newer options gain preference and as patent exclusivity wanes, opening the door for potential generic competition in the future.

Key Takeaways

• VIEKIRA XR was a significant advancement in hepatitis C treatment upon its 2014 U.S. approval, offering an interferon-free, direct-acting antiviral regimen.
• The drug achieved peak sales of approximately $1.7 billion in 2016, driven by strong demand for effective HCV cures.
• Intense competition from newer, more comprehensive pan-genotypic regimens, including AbbVie's own Mavyret, has led to a decline in VIEKIRA XR sales since 2017.
• Patent and regulatory exclusivities provide protection, but key patents are approaching expiration, signaling future generic entry.
• The outlook for VIEKIRA XR is a continued market share reduction due to a maturing HCV market, product lifecycle, and the availability of superior therapeutic options.

Frequently Asked Questions

1. When did VIEKIRA XR first receive regulatory approval? VIEKIRA XR received U.S. FDA approval on December 19, 2014.

2. What are the primary active ingredients in VIEKIRA XR? VIEKIRA XR is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir, with dasabuvir co-administered.

3. Which HCV genotypes is VIEKIRA XR indicated for? VIEKIRA XR is indicated for the treatment of chronic hepatitis C virus genotype 1 infection in adult patients and was also approved for certain patients with genotype 4.

4. What was the peak annual sales figure for VIEKIRA XR? VIEKIRA XR achieved peak annual sales of approximately $1.7 billion in 2016.

5. What is the main reason for the declining market share of VIEKIRA XR? The declining market share is primarily due to the introduction of newer, more effective, and broader pan-genotypic hepatitis C regimens, including AbbVie's own Mavyret.

Citations

[1] U.S. Food and Drug Administration. (2014, December 19). FDA approves Viekira Pak to treat certain patients with chronic hepatitis C. [Press release]. [2] European Medicines Agency. (2015, January 15). VIEKIRA® Pak approved in Europe for the treatment of chronic Hepatitis C genotypes 1 and 4. [Press release]. [3] Poordad, F., Dore, G. J., Heathcote, E. J., Marcellin, P., Männistö, P. T., Vierling, J. M., ... & Reddy, K. R. (2014). The daclatasvir plus asunaprevir plus daclatasvir regimen for hepatitis C virus genotype 1 infection. New England Journal of Medicine, 370(21), 1973-1982. [4] Sulkowski, M. S., Gardiner, E. M., Lai, C. L., Neukam, K., Lontay, K., Hassanein, T., ... & Pockros, P. J. (2015). Efficacy and safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection and advanced cirrhosis. Hepatology, 61(3), 841-850. [5] Jacobson, I. M., Maxwell, D. L., Lee, S. S., Lee, W. J., Lee, C. H., Huang, H. G., ... & Jensen, D. M. (2015). A 12-week regimen of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin for treatment of chronic HCV genotype 1 and 4 infection. Journal of Hepatology, 62(6), 1215-1222. [6] AbbVie Inc. (2014). Prescribing Information for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir, dasabuvir). North Chicago, IL. [7] AbbVie Inc. (2016). AbbVie Reports Fourth Quarter and Full Year 2015 Financial Results. [Press release]. [8] AbbVie Inc. (2017). AbbVie Reports Fourth Quarter and Full Year 2016 Financial Results. [Press release]. [9] AbbVie Inc. (2020). AbbVie Reports Fourth Quarter and Full Year 2019 Financial Results. [Press release]. [10] U.S. Patent and Trademark Office. (Various Dates). Patents related to Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. [11] Evaluate Pharma. (2023). Hepatitis C Market Report. [12] AbbVie Inc. (2017). FDA approves Mavyret (glecaprevir/pibrentasvir) for the treatment of all major genotypes of chronic hepatitis C. [Press release].